Publication: Systemic cytology. A novel diagnostic approach for assessment of early systemic disease
Issued Date
2021-11-01
Resource Type
ISSN
15322777
03069877
03069877
Other identifier(s)
2-s2.0-85115963869
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Medical Hypotheses. Vol.156, (2021)
Suggested Citation
Stefan Schreier, Wannapong Triampo Systemic cytology. A novel diagnostic approach for assessment of early systemic disease. Medical Hypotheses. Vol.156, (2021). doi:10.1016/j.mehy.2021.110682 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77728
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Systemic cytology. A novel diagnostic approach for assessment of early systemic disease
Author(s)
Other Contributor(s)
Abstract
Recognition of low grade or asymptomatic systemic diseases suggests prevention of the worst, yet has been proven challenging ever since. Biomarker-based liquid biopsy has emerged in recent years as a practical platform for the assessment of systemic diseases yet, technical realizations were mainly focused on cancer, faced challenges in accuracy at early stage and are lacking provision of sufficient evidence of disease. In particular in cell-based cancer liquid biopsy, obstacles are rarity and heterogeneity of circulating tumor and tumor-associated rare cells. Evidence is mounting about an entire spectrum of distinct circulating rare cell types that denotes the systemic component of a certain physiological state. Therefore, circulating rare cells in combination may arise from yet, also account for systemic diseases, which we denote as multi-rare cell association and involves foremost bone marrow-derived progenitor and stem cells yet, also matured somatic cell types. One would expect immense diagnostic value in the read-out of the so called rare cell population which represents cytological evidence of abnormality. We hypothesize that comprehensive rare cell population profiling as contrasted to the biomarker screening approach may realize the premise of a biopsy as to confirm, characterize, grade, stage or predict a systemic disease. This novel approach represents the “missing link” in diagnostic care of in particular early or residual systemic disease and presumes a steady gain in knowledge about the clinical interpretation of rare cell population profiles thus, expecting the knowledge-driven transformation of cell-based liquid biopsy from suggestion to confirmation. We support our hypothesis by past findings made by others and us and provide insights how to interpret a certain rare cell population profile.